Journal Article
. 2016 May; 5(4):e70.
doi: 10.1038/cti.2016.16.

OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer

Ryan Montler 1 R Bryan Bell 2 Colin Thalhofer 1 Rom Leidner 2 Zipei Feng 3 Bernard A Fox 4 Allen C Cheng 5 Tuan G Bui 5 Christopher Tucker 6 Helena Hoen 4 Andrew Weinberg 6 
  • PMID: 27195113
  •     29 References
  •     45 citations


The tumor microenvironment of squamous cell carcinoma of the head and neck (SCCHN) has been shown to be immune suppressive. Therefore, strategies aimed at overcoming this issue could have a positive therapeutic impact. Hence, we investigated the expression of the known immune-modulatory proteins OX40, programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) in SCCHN on different T-cell subsets of tumor-infiltrating lymphocytes (TIL) to ascertain whether these proteins could potentially be targeted alone or in combination for future clinical trials. T cells from peripheral blood (PBL) and tumor were analyzed for the expression of OX40, PD-1 and CTLA-4 in 29 patients undergoing surgery. These proteins were all expressed significantly higher in T-cell subsets isolated from tumors compared with PBL of the same patient. OX40 expression was significantly greater in the TIL regulatory T-cell (Treg) population relative to conventional CD4 and CD8 TIL or the Treg isolated from PBL. PD-1 expression was increased in all T-cell subsets relative to PBL. CTLA-4 was also increased in all TIL subsets relative to blood, and similar to OX40, its highest level of expression was observed in the Treg TIL. The highest frequency of PD-1, CTLA-4 and OX40 triple-positive cells were found in the Treg population isolated from the tumor. We analyzed both human papilloma virus-positive and -negative patients and found similar levels and expression patterns of these two patient populations for all three proteins. These data suggest that there may be therapeutic advantages of targeting these pathways independently or in combination for patients with this disease.

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.
Michael A Curran, Welby Montalvo, Hideo Yagita, James P Allison.
Proc Natl Acad Sci U S A, 2010 Feb 18; 107(9). PMID: 20160101    Free PMC article.
Highly Cited.
Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer—review of current data.
Mark S Swanson, Uttam K Sinha.
Oral Oncol, 2014 Dec 03; 51(1). PMID: 25459157
PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer.
Zhiqiang Guo, Xin Wang, +3 authors, Shulan Zhang.
PLoS One, 2014 Mar 04; 9(2). PMID: 24586709    Free PMC article.
Highly Cited.
Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment.
Lawrence Fong, Eric J Small.
J Clin Oncol, 2008 Oct 08; 26(32). PMID: 18838703
Systematic Review.
Immunostimulatory monoclonal antibodies for cancer therapy.
Ignacio Melero, Sandra Hervas-Stubbs, +2 authors, Lieping Chen.
Nat Rev Cancer, 2007 Jan 26; 7(2). PMID: 17251916
Highly Cited. Review.
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
Julie R Brahmer, Charles G Drake, +17 authors, Suzanne L Topalian.
J Clin Oncol, 2010 Jun 03; 28(19). PMID: 20516446    Free PMC article.
Highly Cited.
Targeting OX40 and OX40L for the treatment of autoimmunity and cancer.
William L Redmond, Andrew D Weinberg.
Crit Rev Immunol, 2008 Jan 17; 27(5). PMID: 18197805
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, +27 authors, Mario Sznol.
N Engl J Med, 2012 Jun 05; 366(26). PMID: 22658127    Free PMC article.
Highly Cited.
Toxicity patterns with immunomodulating antibodies and their combinations.
John B A G Haanen, Hans van Thienen, Christian U Blank.
Semin Oncol, 2015 May 13; 42(3). PMID: 25965360
Immune parameters affecting the efficacy of chemotherapeutic regimens.
Laurence Zitvogel, Oliver Kepp, Guido Kroemer.
Nat Rev Clin Oncol, 2011 Mar 03; 8(3). PMID: 21364688
Highly Cited. Review.
Case-control study of human papillomavirus and oropharyngeal cancer.
Gypsyamber D'Souza, Aimee R Kreimer, +5 authors, Maura L Gillison.
N Engl J Med, 2007 May 15; 356(19). PMID: 17494927
Highly Cited.
OX40-mediated memory T cell generation is TNF receptor-associated factor 2 dependent.
Rodney A Prell, Dean E Evans, +3 authors, Andrew D Weinberg.
J Immunol, 2003 Nov 25; 171(11). PMID: 14634111
Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies.
Raanan Berger, Rinat Rotem-Yehudar, +6 authors, Arnon Nagler.
Clin Cancer Res, 2008 May 17; 14(10). PMID: 18483370
Highly Cited.
Cutting Edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right.
Carl E Ruby, Melissa A Yates, +5 authors, Andrew D Weinberg.
J Immunol, 2009 Sep 30; 183(8). PMID: 19786544    Free PMC article.
Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR.
Barbara Valzasina, Cristiana Guiducci, +3 authors, Mario P Colombo.
Blood, 2004 Dec 14; 105(7). PMID: 15591118
Highly Cited.
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies.
Karl S Peggs, Sergio A Quezada, +2 authors, James P Allison.
J Exp Med, 2009 Jul 08; 206(8). PMID: 19581407    Free PMC article.
Highly Cited.
OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor.
Michael J Gough, Carl E Ruby, +3 authors, Andrew D Weinberg.
Cancer Res, 2008 Jul 03; 68(13). PMID: 18593921
Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors.
Stephen R Mattarollo, Sherene Loi, +3 authors, Mark J Smyth.
Cancer Res, 2011 Jun 08; 71(14). PMID: 21646474
Highly Cited.
Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.
Jeffrey Weber.
Semin Oncol, 2010 Nov 16; 37(5). PMID: 21074057
Highly Cited. Review.
Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients.
H-B Jie, N Gildener-Leapman, +4 authors, R L Ferris.
Br J Cancer, 2013 Oct 31; 109(10). PMID: 24169351    Free PMC article.
Highly Cited.
Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor.
J Kjaergaard, L Peng, +3 authors, S Shu.
J Immunol, 2001 Nov 21; 167(11). PMID: 11714839
Breakthrough of the year 2013. Cancer immunotherapy.
Jennifer Couzin-Frankel.
Science, 2013 Dec 21; 342(6165). PMID: 24357284
Highly Cited.
Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells.
Keli L Hippen, Paul Harker-Murray, +14 authors, Bruce R Blazar.
Blood, 2008 Jul 23; 112(7). PMID: 18645038    Free PMC article.
Functional dichotomy between OX40 and 4-1BB in modulating effector CD8 T cell responses.
Seung-Woo Lee, Yunji Park, +3 authors, Michael Croft.
J Immunol, 2006 Sep 20; 177(7). PMID: 16982882
Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma.
Sofia Lyford-Pike, Shiwen Peng, +12 authors, Sara I Pai.
Cancer Res, 2013 Jan 05; 73(6). PMID: 23288508    Free PMC article.
Highly Cited.
Targeting regulatory T cells in tumor immunotherapy.
Mark J Smyth, Shin Foong Ngiow, Michele W L Teng.
Immunol Cell Biol, 2014 Apr 30; 92(6). PMID: 24777313
The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature.
Ronald J deLeeuw, Sara E Kost, Juzer A Kakal, Brad H Nelson.
Clin Cancer Res, 2012 Apr 19; 18(11). PMID: 22510350
Highly Cited. Systematic Review.
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
Julie R Brahmer, Scott S Tykodi, +23 authors, Jon M Wigginton.
N Engl J Med, 2012 Jun 05; 366(26). PMID: 22658128    Free PMC article.
Highly Cited.
OX40 is a potent immune-stimulating target in late-stage cancer patients.
Brendan D Curti, Magdalena Kovacsovics-Bankowski, +20 authors, Andrew D Weinberg.
Cancer Res, 2013 Nov 02; 73(24). PMID: 24177180    Free PMC article.
Highly Cited.
Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer.
Ruth J Davis, Carter Van Waes, Clint T Allen.
Oral Oncol, 2016 May 25; 58. PMID: 27215705    Free PMC article.
Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ.
Amy E Moran, Fanny Polesso, Andrew D Weinberg.
J Immunol, 2016 Aug 10; 197(6). PMID: 27503208    Free PMC article.
Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer.
Dennis O Adeegbe, Yan Liu, +22 authors, Kwok-Kin Wong.
Cancer Discov, 2017 Apr 15; 7(8). PMID: 28408401    Free PMC article.
Highly Cited.
PD-1 Blockade Prevents the Development and Progression of Carcinogen-Induced Oral Premalignant Lesions.
Jin Wang, Tongxin Xie, +5 authors, Carlos Caulin.
Cancer Prev Res (Phila), 2017 Oct 12; 10(12). PMID: 29018057    Free PMC article.
Control of NK Cell Activation by Immune Checkpoint Molecules.
Asma Beldi-Ferchiou, Sophie Caillat-Zucman.
Int J Mol Sci, 2017 Oct 13; 18(10). PMID: 29023417    Free PMC article.
Modulation of antigen presenting cell functions during chronic HPV infection.
Abate Assefa Bashaw, Graham R Leggatt, +2 authors, Ian H Frazer.
Papillomavirus Res, 2017 Nov 29; 4. PMID: 29179871    Free PMC article.
Advances in T-cell checkpoint immunotherapy for head and neck squamous cell carcinoma.
Xinmeng Qi, Bo Jia, Xue Zhao, Dan Yu.
Onco Targets Ther, 2017 Dec 15; 10. PMID: 29238207    Free PMC article.
Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein.
Michael D Oberst, Catherine Augé, +19 authors, Scott A Hammond.
Mol Cancer Ther, 2018 Mar 17; 17(5). PMID: 29545330    Free PMC article.
Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody.
Randi B Gombos, Ana Gonzalez, +24 authors, Nicholas S Wilson.
PLoS One, 2018 Apr 05; 13(4). PMID: 29617360    Free PMC article.
Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model.
Sharareh Niknam, Hampartsoum B Barsoumian, +15 authors, James W Welsh.
Clin Cancer Res, 2018 May 23; 24(22). PMID: 29784675    Free PMC article.
The promise and challenges of immune agonist antibody development in cancer.
Patrick A Mayes, Kenneth W Hance, Axel Hoos.
Nat Rev Drug Discov, 2018 Jun 16; 17(7). PMID: 29904196
Highly Cited. Review.
Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer.
D E Meyers, P M Bryan, S Banerji, D G Morris.
Curr Oncol, 2018 Aug 17; 25(4). PMID: 30111979    Free PMC article.
Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy.
Steven F Gameiro, Farhad Ghasemi, +4 authors, Saman Maleki Vareki.
Oncoimmunology, 2018 Oct 06; 7(10). PMID: 30288365    Free PMC article.
Deciphering the Role of Regulatory CD4 T Cells in Oral and Oropharyngeal Cancer: A Systematic Review.
Caoimhín O'Higgins, Frank J Ward, Rasha Abu Eid.
Front Oncol, 2018 Nov 22; 8. PMID: 30460193    Free PMC article.
Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers.
Bo Yang, Tingjun Liu, +4 authors, Jianbo Sun.
Front Oncol, 2018 Dec 14; 8. PMID: 30547012    Free PMC article.
OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer.
Juan Deng, Sha Zhao, +4 authors, Yayi He.
Onco Targets Ther, 2019 Oct 01; 12. PMID: 31564917    Free PMC article.
CTLA-4 Immunohistochemistry and Quantitative Image Analysis for Profiling of Human Cancers.
Charles Brown, Farzad Sekhavati, +4 authors, Keith E Steele.
J Histochem Cytochem, 2019 Oct 15; 67(12). PMID: 31609157    Free PMC article.
TROP2 increases growth and metastasis of human oral squamous cell carcinoma through activation of the PI3K/Akt signaling pathway.
Genxiong Tang, Qi Tang, +5 authors, Zhengqing Feng.
Int J Mol Med, 2019 Oct 23; 44(6). PMID: 31638186    Free PMC article.
A Comprehensive Analysis of Key Immune Checkpoint Receptors on Tumor-Infiltrating T Cells From Multiple Types of Cancer.
Xi Li, Rouzheng Wang, +25 authors, Tao Dong.
Front Oncol, 2019 Nov 12; 9. PMID: 31709176    Free PMC article.
The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradation.
Dan Yu, Xueshibojie Liu, +6 authors, Lianji Wen.
Cell Commun Signal, 2019 Dec 29; 17(1). PMID: 31881947    Free PMC article.
PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer.
Takahiro Kamada, Yosuke Togashi, +13 authors, Hiroyoshi Nishikawa.
Proc Natl Acad Sci U S A, 2019 Apr 28; 116(20). PMID: 31028147    Free PMC article.
Highly Cited.
Critical role of OX40 signaling in the TCR-independent phase of human and murine thymic Treg generation.
Prabhakaran Kumar, Alejandra Marinelarena, +7 authors, Bellur S Prabhakar.
Cell Mol Immunol, 2018 Mar 27; 16(2). PMID: 29578532    Free PMC article.
Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity.
Yu Fu, Qing Lin, Zhirong Zhang, Ling Zhang.
Acta Pharm Sin B, 2020 Mar 07; 10(3). PMID: 32140389    Free PMC article.
The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia.
Patrick Williams, Sreyashi Basu, +22 authors, Naval G Daver.
Cancer, 2018 Dec 01; 125(9). PMID: 30500073    Free PMC article.
Highly Cited.
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation.
Anne Månsson Kvarnhammar, Niina Veitonmäki, +16 authors, Peter Ellmark.
J Immunother Cancer, 2019 Apr 13; 7(1). PMID: 30975201    Free PMC article.
Regulation of regulatory T cells in cancer.
Julie Stockis, Rahul Roychoudhuri, Timotheus Y F Halim.
Immunology, 2019 Apr 30; 157(3). PMID: 31032905    Free PMC article.
The promise of immunotherapy in the treatment of young adults with oral tongue cancer.
Hassan Nasser, Maie A St John.
Laryngoscope Investig Otolaryngol, 2020 Apr 28; 5(2). PMID: 32337355    Free PMC article.
Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3Kβ Inhibition in PTEN Loss Melanoma.
Weiyi Peng, Leila J Williams, +17 authors, Patrick Hwu.
Clin Cancer Res, 2019 Aug 03; 25(21). PMID: 31371342    Free PMC article.
Immune Evasion by Head and Neck Cancer: Foundations for Combination Therapy.
Joshua D Horton, Hannah M Knochelmann, +2 authors, David M Neskey.
Trends Cancer, 2019 Apr 10; 5(4). PMID: 30961829    Free PMC article.
Immune mechanisms of idiosyncratic drug-induced liver injury.
Alastair Mak, Jack Uetrecht.
J Clin Transl Res, 2017 Feb 12; 3(1). PMID: 30873473    Free PMC article.
Turning the Tide Against Regulatory T Cells.
SeongJun Han, Aras Toker, Zhe Qi Liu, Pamela S Ohashi.
Front Oncol, 2019 May 07; 9. PMID: 31058083    Free PMC article.
Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy.
Sebastian Chrétien, Ioannis Zerdes, +2 authors, Theodoros Foukakis.
Cancers (Basel), 2019 May 08; 11(5). PMID: 31060337    Free PMC article.
Radiotherapy plus EGFR inhibitors: synergistic modalities.
Paolo Bossi, Francesca Platini.
Cancers Head Neck, 2017 Jan 18; 2. PMID: 31093349    Free PMC article.
FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells.
Lucia Campos Carrascosa, Adriaan A van Beek, +19 authors, Jaap Kwekkeboom.
J Immunother Cancer, 2020 Sep 10; 8(2). PMID: 32900860    Free PMC article.
Hyperprogression: A novel response pattern under immunotherapy.
Xue-Jiao Han, Aqu Alu, +2 authors, Xia-Wei Wei.
Clin Transl Med, 2020 Oct 01; 10(5). PMID: 32997401    Free PMC article.
The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer.
Xin-Wei Qiao, Jian Jiang, +4 authors, Ya-Ling Tang.
Front Immunol, 2020 Oct 20; 11. PMID: 33072064    Free PMC article.
Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell Carcinoma.
Barbara Seliger, Chiara Massa, +4 authors, Claudia Wickenhauser.
Int J Mol Sci, 2020 Sep 30; 21(19). PMID: 32987799    Free PMC article.
Tumor Microenvironment and Immunotherapy Response in Head and Neck Cancer.
Panagiota Economopoulou, Ioannis Kotsantis, Amanda Psyrri.
Cancers (Basel), 2020 Nov 19; 12(11). PMID: 33203092    Free PMC article.
Revisiting the role of CD4+ T cells in cancer immunotherapy-new insights into old paradigms.
Rong En Tay, Emma K Richardson, Han Chong Toh.
Cancer Gene Ther, 2020 May 28; 28(1-2). PMID: 32457487    Free PMC article.
Non-canonical PD-1 signaling in cancer and its potential implications in clinic.
Haoran Zha, Ying Jiang, +10 authors, Zhaoxia Li.
J Immunother Cancer, 2021 Feb 18; 9(2). PMID: 33593825    Free PMC article.
Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells.
Rebekka Duhen, Carmen Ballesteros-Merino, +12 authors, Andrew D Weinberg.
Nat Commun, 2021 Feb 18; 12(1). PMID: 33594075    Free PMC article.
Serum Levels of OX40 in Early and Late-Stage Oral Squamous Cell Carcinoma.
Aliya I Sani, Zil E Rubab, +3 authors, Moazzam A Shahid.
Cureus, 2021 May 27; 13(4). PMID: 34036015    Free PMC article.
PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects.
Enrico Munari, Francesca R Mariotti, +9 authors, Lorenzo Moretta.
Int J Mol Sci, 2021 Jun 03; 22(10). PMID: 34066087    Free PMC article.
Generating CAR T cells from tumor-infiltrating lymphocytes.
Jane K Mills, Melissa A Henderson, +6 authors, David E Gyorki.
Ther Adv Vaccines Immunother, 2021 Jun 24; 9. PMID: 34159293    Free PMC article.
Prognostic significance of OX40+ lymphocytes in tumor stroma of surgically resected small-cell lung cancer.
Hiroshi Yokouchi, Hiroshi Nishihara, +21 authors, Hiroshi Isobe.
Oncoimmunology, 2021 Sep 24; 10(1). PMID: 34552823    Free PMC article.